STAAR Surgical (NASDAQ:STAA) Price Target Lowered to $37.00 at Wedbush

Key Points

• Wedbush lowered STAAR Surgical’s price target to $37 from $40 while maintaining an “outperform” rating, implying 45.61% potential upside from the prior close.
• Analyst sentiment is mixed: MarketBeat reports an average “hold” rating and a consensus price target of $26.61, with ratings ranging from strong buy to sell.
• STAAR Surgical exceeded quarterly revenue and EPS estimates, reporting $93.52 million in revenue and $0.10 EPS, while revenue rose 119.6% year over year despite a negative net margin.

STAAR Surgical (NASDAQ:STAA - Get Free Report) had its target price reduced by equities research analysts at Wedbush from $40.00 to $37.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the medical instruments supplier's stock. Wedbush's price target would indicate a potential upside of 45.61% from the company's previous close.

Other research analysts have also recently issued reports about the stock. UBS Group began coverage on shares of STAAR Surgical in a report on Tuesday, July 28th. They issued a "sell" rating and a $20.00 price objective for the company. Canaccord Genuity Group increased their price target on STAAR Surgical from $27.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, May 14th. Wall Street Zen downgraded STAAR Surgical from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Zacks Research upgraded shares of STAAR Surgical from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 4th. Finally, Stifel Nicolaus increased their target price on shares of STAAR Surgical from $18.00 to $31.00 and gave the company a "hold" rating in a research note on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $26.61.

STAAR Surgical Stock Performance

Shares of NASDAQ STAA opened at $25.41 on Thursday. STAAR Surgical has a 12-month low of $15.59 and a 12-month high of $35.87. The company has a current ratio of 5.12, a quick ratio of 4.31 and a debt-to-equity ratio of 0.09. The company has a market cap of $1.27 billion, a PE ratio of -59.09 and a beta of 1.26. The stock has a 50 day simple moving average of $26.98 and a 200-day simple moving average of $24.08.

STAAR Surgical (NASDAQ:STAA - Get Free Report) last announced its earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $0.05. The firm had revenue of $93.52 million during the quarter, compared to analyst estimates of $78.72 million. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.31%. STAAR Surgical's revenue was up 119.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.10) EPS. On average, equities research analysts forecast that STAAR Surgical will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of STAA. American Capital Management Inc. boosted its holdings in STAAR Surgical by 18.7% in the first quarter. American Capital Management Inc. now owns 878,035 shares of the medical instruments supplier's stock worth $16,419,000 after purchasing an additional 138,499 shares in the last quarter. Crcm LP acquired a new stake in shares of STAAR Surgical in the first quarter worth about $1,870,000. Renaissance Technologies LLC lifted its position in shares of STAAR Surgical by 257.7% in the first quarter. Renaissance Technologies LLC now owns 135,200 shares of the medical instruments supplier's stock worth $2,528,000 after buying an additional 97,400 shares during the last quarter. UBS Group AG boosted its stake in shares of STAAR Surgical by 39.2% during the 4th quarter. UBS Group AG now owns 327,852 shares of the medical instruments supplier's stock worth $7,570,000 after acquiring an additional 92,321 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of STAAR Surgical during the 4th quarter worth about $910,000. 96.70% of the stock is owned by institutional investors and hedge funds.

STAAR Surgical News Roundup

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: STAAR reported second-quarter revenue of approximately $93.5 million, exceeding the roughly $90.6 million analyst estimate and increasing more than 100% year over year. Adjusted earnings also surpassed consensus in one widely cited measure, at $0.31 per share versus an expected $0.21, compared with a $0.07 loss a year earlier. STAAR Surgical Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management expects to finish 2026 with well over $200 million in cash, supporting financial flexibility for growth initiatives. It also plans to shift all China-bound supply to Switzerland, which could reduce exposure to geopolitical, tariff and regional production risks over time. STAAR Surgical Plans Cash and Supply-Chain Changes
• Neutral Sentiment: The company’s revenue growth reflects continued demand for its implantable collamer lenses, but investors are evaluating procedure demand and the mix of sales across China and other geographic markets. The earnings call provided additional context on operating performance and 2026 priorities. STAAR Surgical Q2 2026 Earnings Call Transcript
• Negative Sentiment: Reported GAAP earnings were cited at $0.16 per share, below the $0.22 consensus estimate, despite the revenue beat. That bottom-line miss likely contributed to the stock’s decline as investors weighed profitability and execution rather than focusing solely on sales growth. STAAR Surgical Earnings Report
• Negative Sentiment: Moving 100% of China supply to Switzerland may improve resilience, but the transition could introduce manufacturing, logistics and cost risks in the near term.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source